Skip to content

A Message To Our Clients

A Message To Our Clients

To Our Clients,


First of all, I hope everyone is staying safe and healthy in these unprecedented times.  I want to assure you that Arfinn Med has systems in place to ensure that our workflows are not impacted from having staff work remotely and we will continue to provide the same quality product and customer service that you have become accustomed to.  If you have any questions regarding our Business Continuation Plan, please reach out to info@arfinnmed.com.


We understand that routines will be temporarily changed in the coming months, so we are adapting to accommodate this change.  This means building out a more robust telemedicine system, increasing our patient portal functionality,  generating consents to be e-signed, and streamlining our patient intake process to cut down on wait times.  


As we settle into new workflows and challenges, we will suspend all monthly fees for using Arfinn Med until June 1st.  We also will activate our full suite of functionality to all current users so you are able to offer the best care to patients in the interim.  We know this doesn’t seem like much in these times, but we want to show our gratitude to the medical professionals who are on the front lines helping patients get the help they desperately need.  If you haven’t already, you will be seeing these updates on your account over the weekend. 


Please stay safe, and let us know if you require anything to continue running your practices.  I have set aside a development team to continually assess how to improve care and keep stakeholders safe.
Sincerely, 


James West CEO

Stories you may be interested in

Cannabis improves symptoms of Crohn’s disease despite having no effect on gut inflammation

In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation. In a randomised, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission…
Read More →

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More →

Illinois dispensary to allow patients to substitute medical marijuana for opioids prescription

SPRINGFIELD, ILL. (KMOV.com) — Thursday, Illinois will become the first state to launch a revised medical marijuana program. The program allows pain suffers who use opioids to temporarily switch to medical marijuana. Following months of planning, the new initiative will launch at the HCI Alternatives medical cannabis dispensary in Springfield, Illinois. In a press release,…
Read More →

More Treatment Options, Better Patient Outcomes

As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment.  In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More →

Florida medical marijuana dispensary now sells the state’s first cannabis tablet

Even though Florida residents can finally smoke medical marijuana, one of the state’s largest cannabis companies is now offering it in tablet form. The company Curaleaf released the state’s first cannabis tablet on Sunday. The company’s two Orlando locations, at 775 N Semoran Blvd. and 12402 S Orange Blossom Trail, sell the mint-flavored tablets for $35 for a 30-quantity, child-resistant package. Read…
Read More →

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More →

Leave a Comment

You must be logged in to post a comment.